#AIHealthcare #DataIntegration #PatientCare
www.forbes.com
The Patient's Dilemma: Intimacy Vs. Integration In The AI Health Revolution
A patient arrives with months of granular biometric data from wearables - cardiac rhythms, sleep logs, glucose trends. She has information, but not clinical insight.
#AIHealthcare #StartupSuccess #MedicalInnovation
www.forbes.com
OpenEvidence Founder Doubles His Wealth As Medical AI Startup Hits $12 Billion Valuation
hree years ago, Daniel Nadler launched OpenEvidence, an AI-based search tool that helps doctors get answers to complicated clinical questions quickly and easily.
#AIHealthcare #ChatGPT #MedicalAdvice
www.zdnet.com
40 million people globally are using ChatGPT for healthcare - but is it safe?
5% of messages to ChatGPT globally concern healthcare. Users ask about symptoms and insurance advice, for example. Chatbots can provide dangerously inaccurate information.
#MedicalTechnology #AIHealthcare #BladderCancer
markets.businessinsider.com
CystoSmart™, an AI Software Tool for Bladder Cancer Detection, Developed with Cutting-Edge Technology Receives Clearance from Health Sciences Authority Singapore
SINGAPORE and LONDON and NEW YORK, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp ("ISC"), specializing in state-of-the-art image enhancement and precision AI software solutions for urology and gastroenterology, is pleased to announce that CystoSmart™ has received regulatory clearance from Health Sciences Authority (HSA), the National Regulatory Agency for medical products and devices in Singapore.
#MedicalDevices #AIHealthcare #BladderCancer
www.benzinga.com
CystoSmart™, an AI Software Tool for Bladder Cancer Detection, Developed with Cutting-Edge Technology Receives Clearance from Health Sciences Authority Singapore
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
SINGAPORE and LONDON and NEW YORK, Jan.
#MedicalDevices #AIHealthcare #BladderCancer
www.benzinga.com
CystoSmart™, an AI Software Tool for Bladder Cancer Detection, Developed with Cutting-Edge Technology Receives Clearance from Health Sciences Authority Singapore
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
SINGAPORE and LONDON and NEW YORK, Jan.
